What is SomaLogic?
SomaLogic operates at the forefront of proteomics, a field critical for understanding biological processes and disease. The company's proprietary platform is engineered for comprehensive and efficient proteomic analysis, offering a powerful tool for researchers and clinicians. By enabling detailed insights into the proteome, SomaLogic is contributing to advancements in diagnostics, drug discovery, and personalized medicine. Its technology addresses key challenges in the field, promising to accelerate scientific breakthroughs and improve patient outcomes.
How much funding has SomaLogic raised?
SomaLogic has raised a total of $1.3B across 11 funding rounds:
Private Equity
$10M
Unspecified
$1M
Private Equity
$16.5M
Private Equity
$60.5M
Private Equity
$163M
Private Equity
$44.9M
Private Equity
$200M
Debt
$2M
Series A
$214M
Stock Offering
$630M
Private Equity (2013): $10M, investors not publicly disclosed
Unspecified (2014): $1M supported by Bill & Melinda Gates Foundation
Private Equity (2014): $16.5M, investors not publicly disclosed
Private Equity (2016): $60.5M backed by Visium Healthcare Partners
Private Equity (2016): $163M, investors not publicly disclosed
Private Equity (2017): $44.9M, investors not publicly disclosed
Private Equity (2018): $200M supported by Nan Fung Life Sciences, iCarbonX, Otsuka Pharmaceutical, Visium Healthcare Partners, Madryn Asset Management, ProQuest Investments, and Quest Diagnostics
Debt (2020): $2M featuring PPP
Series A (2020): $214M backed by Soleus Capital, Madryn Asset Management, T. Rowe Price Associates, Mossrock Capital, Boston Millennia Partners, Farallon Capital Management, Janus Henderson Group, Logos Capital, Redmile Group, Revelation Partners, Foresite Capital, Remagine Ventures, Blue Water Life Science Advisors, Fiscus Ventures, Casdin Capital, Ziff Capital Healthcare Ventures, Monashee Investment Management, and Millennium Management
Stock Issuance/Offering (2021): $630M with participation from Corvex Management, SB Management, T. Rowe Price, Janus Henderson Group, and Casdin Capital
Key Investors in SomaLogic
Corvex Management
Corvex Management, LP is an investment firm founded in 2010 and headquartered in New York City, New York, likely focusing on strategic equity investments.
T. Rowe Price
T. Rowe Price Group, established in 1937, is a global asset management firm providing investment services to a wide range of clients, including institutional investors.
Janus Henderson Group
Janus Henderson Group is a global asset management company formed through the merger of Janus Capital Group and Henderson Group, with a history dating back to 1934.
What's next for SomaLogic?
With the infusion of $630M in a major strategic investment, SomaLogic is poised for accelerated growth and further platform development. This capital injection is expected to fuel expansion into new markets, enhance its technological capabilities, and deepen its research collaborations. The company's focus on providing scalable and cost-effective proteomics solutions positions it to capitalize on the increasing demand for advanced biological insights. SomaLogic's trajectory suggests a continued emphasis on innovation and strategic partnerships to solidify its leadership in the proteomics landscape.
See full SomaLogic company page
